medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2025-295medsovet-9360Research ArticleЭНДОКРИНОЛОГИЯENDOCRINOLOGYТерапия сахарного диабета 2-го типа у коморбидных пациентов: место ситаглиптинаTherapy of type 2 diabetes mellitus in comorbid patients: The place of sitagliptinhttps://orcid.org/0000-0001-6678-6411ДолгихЮ. А.DolgikhYu. A.

Долгих Юлия Александровна, к.м.н., доцент кафедры эндокринологии и гериатрии

 

Yulia A. Dolgikh, Cand. Sci. (Med.), Associate Professor of Department of Endocrinology and Geriatrics

89, Chapaevskaya St., Samara, 443099

yu.a.dolgikh@samsmu.ruhttps://orcid.org/0000-0003-0027-1786БулгаковаС. В.BulgakovaS. V.

Булгакова Светлана Викторовна, д.м.н., доцент, заведующая кафедрой эндокринологии и гериатрии

443099, Самара, ул. Чапаевская, д. 89

Svetlana V. Bulgakova, Dr. Sci. (Med.), Associate Professor, Head of Department of Endocrinology and Geriatrics

89, Chapaevskaya St., Samara, 443099

osteoporosis63@gmail.comhttps://orcid.org/0000-0001-8827-4919ШароноваЛ. А.SharonovaL. A.

Шаронова Людмила Александровна, к.м.н., доцент кафедры эндокринологии и гериатрии

443099, Самара, ул. Чапаевская, д. 89

Lyudmila A. Sharonova, Cand. Sci. (Med.), Associate Professor of Department of Endocrinology and Geriatrics

89, Chapaevskaya St., Samara, 443099

l.a.sharonova@samsmu.ruhttps://orcid.org/0009-0006-4531-9682КосареваО. В.KosarevaO.

Косарева Ольга Владиславовна, к.м.н., доцент кафедры эндокринологии и гериатрии

443099, Самара, ул. Чапаевская, д. 89

Olga V. Kosareva, Cand. Sci. (Med.), Associate Professor of Department of Endocrinology and Geriatrics

89, Chapaevskaya St., Samara, 443099

o.v.kosareva@samsmu.ruhttps://orcid.org/0000-0003-0097-7252ТреневаЕ. В.TrenevaE. V.

Тренева Екатерина Вячеславовна, к.м.н., доцент кафедры эндокринологии и гериатрии

443099, Самара, ул. Чапаевская, д. 89

Ekaterina V. Treneva, Cand. Sci. (Med.), Associate Professor of Department of Endocrinology and Geriatrics

89, Chapaevskaya St., Samara, 443099

eka1006@yandex.ruhttps://orcid.org/0009-0004-6243-6528МерзловаП. Я.MerzlovaP. Ya.

Мерзлова Полина Ярославовна, ассистент кафедры эндокринологии и гериатрии

443099, Самара, ул. Чапаевская, д. 89

Polina Ya. Merzlova, Assistant of Department of Endocrinology and Geriatrics

89, Chapaevskaya St., Samara, 443099

p.ya.merzlova@samsmu.ruhttps://orcid.org/0000-0003-4114-5233КурмаевД. П.KurmaevD. P.

Курмаев Дмитрий Петрович, к.м.н., ассистент кафедры эндокринологии и гериатрии

443099, Самара, ул. Чапаевская, д. 89

Dmitriy P. Kurmaev, Cand. Sci. (Med.), Assistant of Department of Endocrinology and Geriatrics

89, Chapaevskaya St., Samara, 443099

geriatry@mail.ruСамарский государственный медицинский университетРоссияSamara State Medical UniversityRussian Federation2025100920251913150156Copyright © Долгих Ю.А., Булгакова С.В., Шаронова Л.А., Косарева О.В., Тренева Е.В., Мерзлова П.Я., Курмаев Д.П., 20252025Долгих Ю.А., Булгакова С.В., Шаронова Л.А., Косарева О.В., Тренева Е.В., Мерзлова П.Я., Курмаев Д.П.Dolgikh Y.A., Bulgakova S.V., Sharonova L.A., Kosareva O., Treneva E.V., Merzlova P.Y., Kurmaev D.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/9360

Сахарный диабет (СД) 2-го типа отличается высоким уровнем коморбидности. Частыми сопутствующими патологиями у лиц с СД2 являются заболевания сердечно-сосудистой системы, также часто встречаются заболевания органов пищеварения (хронический панкреатит, стеатоз печени, хронический гастрит), патология мочевыделительной и дыхательной систем, сопутствующие эндокринные заболевания, нарушения опорно-двигательного аппарата, патология нервной системы, апноэ во сне. Важными задачами лечения пациентов с СД2 являются также снижения рисков осложнений, сохранение функции β-клеток, увеличение продолжительности жизни и сохранение ее качества. Учитывая коморбидность пациентов с СД2 и, как следствие, применение большого количества препаратов, необходимо, чтобы гипогликемическая терапия была безопасной, хорошо переносилась, не оказывала негативного влияния на другие заболевания и не взаимодействовала с другими препаратами. Ситаглиптин продемонстрировал протективные свойства в отношении сохранения функции β-клеток, а также показал свою безопасность при применении у лиц пожилого возраста, пациентов с сердечно-сосудистыми заболеваниями и умеренными нарушениями функции печени и почек. Кроме того, есть данные, что ситаглиптин имеет потенциальный кардиопротективный эффект, который был показан в исследованиях на животных. Таким образом, ситаглиптин может назначаться достаточно широкому кругу пациентов. В настоящий момент в России зарегистрирован только один препарат ситаглиптина, который полностью идентичен оригинальному, который выпускается в дозе 100 мг и принимается 1 раз в сутки, независимо от приема пищи. Такой режим дозирования удобен и повышает комплаентность пациента.

Diabetes mellitus (DM) type 2 is characterized by a high level of comorbidity. Frequent concomitant pathologies in individuals with DM type 2 are cardiovascular diseases, as well as diseases of the digestive system (chronic pancreatitis, liver steatosis, chronic gastritis), pathology of the urinary and respiratory systems, concomitant endocrine diseases, disorders of the musculoskeletal system, pathology of the nervous system, sleep apnea. Important tasks in the treatment of patients with DM type 2 are also to reduce the risk of complications, preserve the function of β-cells, increase life expectancy and maintain its quality. Given the comorbidity of patients with DM type 2 and, as a result, the use of a large number of drugs, it is necessary that hypoglycemic therapy is safe, well tolerated, does not have a negative effect on other diseases and does not interact with other drugs. Sitagliptin has demonstrated protective properties in terms of preserving β-cell function and has also proven its safety when used in elderly people, patients with cardiovascular diseases and moderate hepatic and renal impairment. In addition, there is evidence that sitagliptin has a potential cardioprotective effect, which has been shown in animal studies. Thus, sitagliptin can be prescribed to a fairly wide range of patients. Currently, only one sitagliptin drug is registered in Russia, which is completely identical to the original one – this is the drug Xelevia. The drug is available in a dose of 100 mg and is taken once a day, regardless of food intake. This dosing regimen is convenient and increases patient compliance.

ингибиторы дипептидилпептидазы-4сердечно-сосудистые заболеванияхроническая болезнь почекгипогликемияситаглиптинdipeptidyl peptidase-4 inhibitorscardiovascular diseaseschronic kidney diseasehypoglycemiasitagliptinReferencesДрапкина ОМ, Шутов АМ, Ефремова ЕВ. Коморбидность, мультиморбидность, двойной диагноз – синонимы или разные понятия? Кардиоваскулярная терапия и профилактика. 2019;18(2):65–69. http://doi.org/10.15829/17288800201926569.Drapkina OM, Shutov AM, Efremova EV. Comorbidity, multimorbidity, dual diagnosis – synonyms or different terms? Cardiovascular Therapy and Prevention. 2019;18(2):65–69. (In Russ.) http://doi.org/10.15829/17288800201926569.Курникова ИА, Трусов ВВ, Чернышова ТЕ. Количественная оценка реабилитационных возможностей организма больных сахарным диабетом. Фундаментальные исследования. 2010;(2):45–51. Режим доступа: https://fundamental-research.ru/ru/article/view?id=1635.Kournikova IA, Trusov VV, Chernyshova TE. Quantitative assessment rehabilitation facilities constitution of diabetes mellitus patients. Fundamental Research. 2010;(2):45–51. (In Russ.) Available at: https://fundamental-research.ru/ru/article/view?id=1635.Мадянов ИВ. Индекс коморбидности CHARLSON при сахарном диабете 2-го типа и его связь с некоторыми особенностями течения заболевания. Здравоохранение Чувашии. 2022;(2):27–33. https://doi.org/10.25589/GIDUV.2022.40.54.012.Madyanov IV. Сharlson comorbidity index in type 2 diabetes mellitus and its relationship with some features of the disease course. Healthcare of Chuvashia. 2022;(2):27–33. (In Russ.) https://doi.org/10.25589/GIDUV.2022.40.54.012.Ахмадуллина ГИ, Курникова ИА. Коморбидная патология у пациентов с сахарным диабетом 2 типа: обсуждаем проблему и пути ее решения. Международный научно-исследовательский журнал. 2022;(2):77–84. https://doi.org/10.23670/IRJ.2022.116.2.047.Akhmadullina GI, Kournikova IA. Comorbid pathology in patients with type 2 diabetes mellitus: a discussion of the problem and its solutions. International Research Journal. 2022;(2):77–84. (In Russ.) https://doi.org/10.23670/IRJ.2022.116.2.047.Учеваткина ТВ, Есина МВ, Величко МА, Савочкина МГ. Анализ коморбидности при сахарном диабете. Актуальные научные исследования в современном мире. 2022;(1-2):140–144. Режим доступа: https://elibrary.ru/ltzrts.Uchevatkina TV, Esina MV, Velichko MA, Savochkina MG. Analysis of comorbidity in diabetes mellitus. Actual Scientific Research in the Modern World. 2022;(1-2):140–144. (In Russ.) Available at: https://elibrary.ru/ltzrts.Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18(9):525–539. https://doi.org/10.1038/s41574-022-00690-7.Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18(9):525–539. https://doi.org/10.1038/s41574-022-00690-7.Корсакова ДА, Гауэрт ВР. Оценка клинических показателей и качества жизни у пациентов с хронической сердечной недостаточностью с коморбидностью по сахарному диабету 2 типа. Российский кардиологический журнал. 2023;28(Suppl. 7):39–40. Режим доступа: https://elibrary.ru/zuzrkc.Korsakova DA, Gauert VR. Assessment of clinical indicators and quality of life in patients with chronic heart failure with comorbidity of type 2 diabetes mellitus. Russian Journal of Cardiology. 2023;28(Suppl. 7):39–40. (In Russ.) Available at: https://elibrary.ru/zuzrkc.Климонтов ВВ. Влияние вариабельности гликемии на риск развития сердечно-сосудистых осложнений при сахарном диабете. Кардиология. 2018;58(10):80–87. https://doi.org/10.18087/cardio.2018.10.10152.Klimontov VV. Impact of Glycemic Variability on Cardiovascular Risk in Diabetes. Kardiologiya. 2018;58(10):80–87. (In Russ.) https://doi.org/10.18087/cardio.2018.10.10152.Wong ND, Patao C, Wong K, Malik S, Franklin SS, Iloeje U. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status. Diab Vasc Dis Res. 2013;10(6):505–513. https://doi.org/10.1177/1479164113496828.Wong ND, Patao C, Wong K, Malik S, Franklin SS, Iloeje U. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status. Diab Vasc Dis Res. 2013;10(6):505–513. https://doi.org/10.1177/1479164113496828.American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl. 1):S144–S174. https://doi.org/10.2337/dc22-S010.American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl. 1):S144–S174. https://doi.org/10.2337/dc22-S010.Дедов ИИ, Шестакова МВ, Майоров АЮ, Мокрышева НГ, Андреева ЕН, Безлепкина ОБ и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023;26(2 Suppl.):1–157. https://doi.org/10.14341/DM13042.Dedov II, Shestakova MV, Mayorov AYu, Mokrysheva NG, Andreeva EN, Bezlepkina OB et al. Standards of Specialized Diabetes Care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th Edition. Diabetes Mellitus. 2023;26(2 Suppl.):1–157. (In Russ.) https://doi.org/10.14341/DM13042.Ferrannini E. The stunned beta cell: a brief history. Cell Metab. 2010;11(5):349–352. https://doi.org/10.1016/j.cmet.2010.04.009.Ferrannini E. The stunned beta cell: a brief history. Cell Metab. 2010;11(5):349–352. https://doi.org/10.1016/j.cmet.2010.04.009.Butler AE, Janso J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110. https://doi.org/10.2337/diabetes.52.1.102.Butler AE, Janso J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110. https://doi.org/10.2337/diabetes.52.1.102.Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100(5):1166–1173. https://doi.org/10.1172/JCI119628.Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100(5):1166–1173. https://doi.org/10.1172/JCI119628.Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(Suppl. 4):32–42. https://doi.org/10.1111/j.1463-1326.2008.00969.x.Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(Suppl. 4):32–42. https://doi.org/10.1111/j.1463-1326.2008.00969.x.Brown RJ, Rother KI. Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes. 2008;9(3):14–22. https://doi.org/10.1111/j.1399-5448.2007.00272.Brown RJ, Rother KI. Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes. 2008;9(3):14–22. https://doi.org/10.1111/j.1399-5448.2007.00272.Derosa G, Carbone A, D’Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. Expert Opin Pharmacother. 2012;13(17):2433–2442. https://doi.org/10.1517/14656566.2012.730519.Derosa G, Carbone A, D’Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. Expert Opin Pharmacother. 2012;13(17):2433–2442. https://doi.org/10.1517/14656566.2012.730519.Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2012;98(1):51–60. https://doi.org/10.1016/j.diabres.2012.05.022.Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2012;98(1):51–60. https://doi.org/10.1016/j.diabres.2012.05.022.Ohkura T, Fujioka Y, Sumi K, Nakanishi R, Shiochi H, Yamamoto N et al. Sitagliptin Improves the Impaired Acute Insulin Response during a Meal Tolerance Test in Japanese Patients with Type 2 Diabetes Mellitus: A SmallScale Real-World Study. Diabetes Ther. 2014;5(1):285–297. https://doi.org/10.1007/s13300-014-0071-1.Ohkura T, Fujioka Y, Sumi K, Nakanishi R, Shiochi H, Yamamoto N et al. Sitagliptin Improves the Impaired Acute Insulin Response during a Meal Tolerance Test in Japanese Patients with Type 2 Diabetes Mellitus: A SmallScale Real-World Study. Diabetes Ther. 2014;5(1):285–297. https://doi.org/10.1007/s13300-014-0071-1.Дедов ИИ, Шестакова МВ, Викулова ОК, Железнякова АВ, Исаков МА. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–221. https://doi.org/10.14341/DM12759.Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MА. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes Mellitus. 2021;24(3):204–221. (In Russ.) https://doi.org/10.14341/DM12759.Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR et al. Rationale, design, and organization of a randomized, controlled trial evaluating cardiovascular outcomes with sitagliptin (tecos) in patients with type 2 diabetes and established cardiovascular risks. Am Heart J. 2013;166(6):983–989.e7. https://doi.org/10.1016/j.ahj.2013.09.003.Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR et al. Rationale, design, and organization of a randomized, controlled trial evaluating cardiovascular outcomes with sitagliptin (tecos) in patients with type 2 diabetes and established cardiovascular risks. Am Heart J. 2013;166(6):983–989.e7. https://doi.org/10.1016/j.ahj.2013.09.003.Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232−242. https://doi.org/10.1056/NEJMoa1501352.Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232−242. https://doi.org/10.1056/NEJMoa1501352.McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB et al.; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016;1(2):126–135. https://doi.org/10.1001/jamacardio.2016.0103.McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB et al.; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016;1(2):126–135. https://doi.org/10.1001/jamacardio.2016.0103.Arnets L, Hage C, Brismar K, Catrina SB, Catrina SB, Norhammar A et al. Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study. Diab Vasc Dis Res. 2016;13(4):307−311. https://doi.org/10.1177/1479164116635997.Arnets L, Hage C, Brismar K, Catrina SB, Catrina SB, Norhammar A et al. Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study. Diab Vasc Dis Res. 2016;13(4):307−311. https://doi.org/10.1177/1479164116635997.Hage C, Brismar K, Efendic S, Lundman P, Rydén L, Mellbin L. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities – the BEGAMI study. J Intern Med. 2013;273(4):410–421. https://doi.org/10.1111/joim.12032.Hage C, Brismar K, Efendic S, Lundman P, Rydén L, Mellbin L. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities – the BEGAMI study. J Intern Med. 2013;273(4):410–421. https://doi.org/10.1111/joim.12032.Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol. 2012;109(11):1681−1685. https://doi.org/10.1016/j.amjcard.2012.01.398.Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol. 2012;109(11):1681−1685. https://doi.org/10.1016/j.amjcard.2012.01.398.Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism. 2014;63(9):1141−1148. https://doi.org/10.1016/j.metabol.2014.06.004.Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism. 2014;63(9):1141−1148. https://doi.org/10.1016/j.metabol.2014.06.004.Omoto S, Taniura T, Nishizawa T, Tamaki T, Shouzu A, Nomura S. Antiatherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2015;8:339–345. https://doi.org/10.2147/DMSO.S84545.Omoto S, Taniura T, Nishizawa T, Tamaki T, Shouzu A, Nomura S. Antiatherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2015;8:339–345. https://doi.org/10.2147/DMSO.S84545.Al-Rasheed NM, Al-Rasheed NM, Hasan IH, Al-Amin MA, Al-Ajmi HN, Mahmoud AM. Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats. Drug Des Devel Ther. 2016;10:2095–2107. https://doi.org/10.2147/DDDT.S109287.Al-Rasheed NM, Al-Rasheed NM, Hasan IH, Al-Amin MA, Al-Ajmi HN, Mahmoud AM. Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats. Drug Des Devel Ther. 2016;10:2095–2107. https://doi.org/10.2147/DDDT.S109287.Vittone F, Liberman A, Vasic D, Ostertag R, Esser M, Walcher D et al. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia. 2012;55(8):2267–2275. https://doi.org/10.1007/s00125-012-2582-5.Vittone F, Liberman A, Vasic D, Ostertag R, Esser M, Walcher D et al. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia. 2012;55(8):2267–2275. https://doi.org/10.1007/s00125-012-2582-5.Russo GT, De Cosmo S, Viazzi F, Mirijello A, Ceriello A et al.; AMD-Annals Study Group. Diabetic kidney disease in the elderly: prevalence and clinical correlates. BMC Geriatr. 2018;18(1):38. https://doi.org/10.1186/s12877-018-0732-4.Russo GT, De Cosmo S, Viazzi F, Mirijello A, Ceriello A et al.; AMD-Annals Study Group. Diabetic kidney disease in the elderly: prevalence and clinical correlates. BMC Geriatr. 2018;18(1):38. https://doi.org/10.1186/s12877-018-0732-4.Kothny W, Lukashevich V, Foley JE, Rendell MS, Schweizer A. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia. 2015;58(9):2020–2026. https://doi.org/10.1007/s00125-015-3655-z.Kothny W, Lukashevich V, Foley JE, Rendell MS, Schweizer A. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia. 2015;58(9):2020–2026. https://doi.org/10.1007/s00125-015-3655-z.Liu W, Yu J, Yan Q, Wang L, Li N, Xiong W. Meta-analysis of the benefit of sitagliptin treatment in patients with type 2 diabetes complicated with incipient nephropathy. Exp Ther Med. 2018;16(3):2545–2553. https://doi.org/10.3892/etm.2018.6449.Liu W, Yu J, Yan Q, Wang L, Li N, Xiong W. Meta-analysis of the benefit of sitagliptin treatment in patients with type 2 diabetes complicated with incipient nephropathy. Exp Ther Med. 2018;16(3):2545–2553. https://doi.org/10.3892/etm.2018.6449.Mori H, Okada Y, Arao T, Tanaka Y. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5(3):313–319. https://doi.org/10.1111/jdi.12142.Mori H, Okada Y, Arao T, Tanaka Y. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5(3):313–319. https://doi.org/10.1111/jdi.12142.Wexler DJ, de Boer IH, Ghosh A, Younes N, Bebu I; GRADE Research Group. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. JAMA Intern Med. 2023;183(7):705–714. https://doi.org/10.1001/jamainternmed.2023.1487.Wexler DJ, de Boer IH, Ghosh A, Younes N, Bebu I; GRADE Research Group. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. JAMA Intern Med. 2023;183(7):705–714. https://doi.org/10.1001/jamainternmed.2023.1487.Ashraf A, Akhtar T, Shabbir A, Aftab U, Shahzad M. Sitagliptin ameliorates diabetic nephropathy by upregulating renal nephrin and podocin expression through modulation of adipokines levels. Fundam Clin Pharmacol. 2023;37(3):549–555. https://doi.org/10.1111/fcp.12864.Ashraf A, Akhtar T, Shabbir A, Aftab U, Shahzad M. Sitagliptin ameliorates diabetic nephropathy by upregulating renal nephrin and podocin expression through modulation of adipokines levels. Fundam Clin Pharmacol. 2023;37(3):549–555. https://doi.org/10.1111/fcp.12864.Mohamed RH, Sedky AA, Hamam GG, Elkhateb L, Kamar SA, Adel S, Tawfik SS. Sitagliptin’s renoprotective effect in a diabetic nephropathy model in rats: The potential role of PI3K/AKT pathway. Fundam Clin Pharmacol. 2022;36(2):324–337. https://doi.org/10.1111/fcp.12736.Mohamed RH, Sedky AA, Hamam GG, Elkhateb L, Kamar SA, Adel S, Tawfik SS. Sitagliptin’s renoprotective effect in a diabetic nephropathy model in rats: The potential role of PI3K/AKT pathway. Fundam Clin Pharmacol. 2022;36(2):324–337. https://doi.org/10.1111/fcp.12736.Wang D, Zhang G, Chen X, Wei T, Liu C, Chen C et al. Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway. Int J Mol Med. 2018;41(5):2784–2792. https://doi.org/10.3892/ijmm.2018.3504.Wang D, Zhang G, Chen X, Wei T, Liu C, Chen C et al. Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway. Int J Mol Med. 2018;41(5):2784–2792. https://doi.org/10.3892/ijmm.2018.3504.Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol Res. 2011;41(6):524–529. https://doi.org/10.1111/j.1872-034X.2011.00798.x.Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol Res. 2011;41(6):524–529. https://doi.org/10.1111/j.1872-034X.2011.00798.x.Fukuhara T, Hyogo H, Ochi H, Fujino H, Kan H, Naeshiro N et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology. 2014;61(130):323–328. Available at: https://pubmed.ncbi.nlm.nih.gov/24901133.Fukuhara T, Hyogo H, Ochi H, Fujino H, Kan H, Naeshiro N et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology. 2014;61(130):323–328. Available at: https://pubmed.ncbi.nlm.nih.gov/24901133.Zhang Y, Cai T, Zhao J, Guo C, Yao J, Gao P et al. Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Horm Metab Res. 2020;52(7):517–526. https://doi.org/10.1055/a-1186-0841.Zhang Y, Cai T, Zhao J, Guo C, Yao J, Gao P et al. Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Horm Metab Res. 2020;52(7):517–526. https://doi.org/10.1055/a-1186-0841.Quartuccio M, Buta B, Kalyani RR. Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. Curr Geri Rep. 2017;6:175–186. https://doi.org/10.1007/s13670-017-0215-z.Quartuccio M, Buta B, Kalyani RR. Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. Curr Geri Rep. 2017;6:175–186. https://doi.org/10.1007/s13670-017-0215-z.Rizzo MR, Barbieri M, Fava I, Desiderio M, Coppola C, Marfella R, Paolisso G. Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors. J Am Med Dir Assoc. 2016;17(10):896–901. https://doi.org/10.1016/j.jamda.2016.04.016.Rizzo MR, Barbieri M, Fava I, Desiderio M, Coppola C, Marfella R, Paolisso G. Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors. J Am Med Dir Assoc. 2016;17(10):896–901. https://doi.org/10.1016/j.jamda.2016.04.016.Round EM, Engel SS, Golm GT, Davies MJ, Kaufman KD, Goldstein BJ. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014;31(3):203–214. https://doi.org/10.1007/s40266-014-0155-7.Round EM, Engel SS, Golm GT, Davies MJ, Kaufman KD, Goldstein BJ. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014;31(3):203–214. https://doi.org/10.1007/s40266-014-0155-7.Umezawa S, Kubota A, Maeda H, Kanamor A. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study. BMC Endocr Disord. 2015;15:34. https://doi.org/10.1186/s12902-015-0033-2.Umezawa S, Kubota A, Maeda H, Kanamor A. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study. BMC Endocr Disord. 2015;15:34. https://doi.org/10.1186/s12902-015-0033-2.

The authors declare that there are no conflicts of interest present.